| Date | Time | Source | Announcement |
|---|---|---|---|
| 16 May 2022 | 07:15 AM | Company Update | |
| 03 May 2022 | 07:00 AM | Collaborative Research Agreement with Organips | |
| 29 Apr 2022 | 07:00 AM | Posting of Annual Report | |
| 25 Apr 2022 | 07:00 AM | Genflow to Present at LLWC 2022 | |
| 29 Mar 2022 | 07:15 AM | New Research Collaboration | |
| 16 Mar 2022 | 07:15 AM | Non-Dilutive Grant Research Award | |
| 18 Jan 2022 | 01:28 PM | Notification of Major Holdings | |
| 17 Jan 2022 | 07:00 AM | First Day of Dealings |
Genflow Biosciences Plc is a UK-based biotechnology company focused on developing gene therapies to combat aging and age-related diseases in humans and dogs. They have R&D facilities in Belgium and a U.S. office in Cambridge, MA. The company's lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene to potentially halt or slow the aging process.
Genflow share price launched at 12p in 2022.